Simtra BioPharma Solutions Capacity Update October 2024: ADC

Simtra BioPharma Solutions is a leading Contract Development and Manufacturing Organization (CDMO) with over 65 years of expertise in sterile injectable products. Our dedicated focus spans a comprehensive range of services, from product development to clinical and commercial fill/finish operations. We are committed to delivering vital injectable therapies to patients around the world.

To better serve pharmaceutical and biotechnology companies, Simtra is expanding its capabilities at both of our sites in Bloomington, Indiana, and Halle/Westfalen, Germany. This expansion aims to enhance our ability to design high-quality products and establish reliable manufacturing processes that consistently ensure optimal product performance. Our goal is to create a fully integrated service offering that positions us as a strategic partner, enabling our clients to expedite their clinical trials and achieve timely product approvals.

Additionally, Simtra has extensive experience in the fill/finish of Antibody-Drug Conjugates (ADCs). We are excited to announce that we are further expanding our offerings by developing clinical-scale capabilities for Conjugation and Purification, with plans to be operational by late 2025. For more details, read our latest announcement here: Simtra BioPharma Solutions Expands Capabilities with $14M.